






Tukavo 50 Tablet
Product Summary :
Tukavo 50 Tablet is an anticancer medicine containing tucatinib that is used to treat HER2-positive breast cancer. It is used for adult patients where surgery can not be performed or in conditions where cancer has already spread to different body parts. It works by blocking the HER2 protein that is responsible for cancer cell growth. It is usually taken twice a day (every 12 hours), with or without food. Take it exactly as prescribed by the doctor. Common side effects include diarrhea, nausea, vomiting, and rash, among others. Do not take it if you are pregnant or breastfeeding. Inform your doctor if you have existing kidney or liver problems before taking this medicine.Written By Dr. Nikita Saini, MBA, MDS,
Reviewed By Dr. Dheeraj Kumar Sharma, PhD, M.Pharm,
Last updated on 25 Oct 2026 | 01:03 AM (IST)
Save more with additional offers







General Information







Product introduction
HER2-positive cells are the cells that have HER2 protein, which may cause cancer to grow quickly if they are present in high quantities. Tukavo 50 Tablet acts on these cells by blocking their activities, which may slow or stop the cancer from growing and spreading.
Take Tukavo 50 Tablet exactly as prescribed by your doctor. It is usually taken twice a day at about the same time each day (at a gap of 12 hours) with or without food. Take it regularly and do not change the dose or stop treatment unless advised by your doctor.
Common side effects of Tukavo 50 Tablet may include diarrhea, nausea, vomiting, and rash. Drink enough fluids to prevent dehydration in case of diarrhea. Inform your doctor if diarrhea is severe or it continues.
Tukavo 50 Tablet may require regular liver function tests during treatment. Inform your doctor if you have any liver disease, all medicines, supplements, and herbal products you take. Tukavo 50 Tablet can harm an unborn baby; it should not be used during pregnancy unless specifically advised by your doctor. Men and women should use effective contraception during treatment and for at least 1 week after the last dose. Breastfeeding should be discontinued during treatment and for 1 week after the last dose.
Uses of Tukavo Tablet
- Treatment of Breast cancer : Tukavo 50 Tablet is used to slow the growth and spread of HER2-positive breast cancer. It is specifically used in cases where cancer has spread to other body parts such as the brain or it cannot be surgically removed.
Benefits of Tukavo Tablet
Breast cancer may develop when abnormal breast cells grow uncontrollably and may spread to other parts of the body. Tukavo 50 Tablet helps slow cancer cell growth and makes it harder for them to survive. This may help control the disease and also slow down its progression, which can help improve overall outcomes of the treatment.
Side effects of Tukavo Tablet
- Diarrhea
- Nausea
- Vomiting
- Increased liver enzymes
- Rash
- Decreased appetite
How to use Tukavo Tablet
How Tukavo Tablet works
Dosage
Tukavo 50 Tablet is usually taken twice daily, keeping a 12-hour gap between doses, or at the same times each day, as prescribed by your doctor depending on your condition and how well you tolerate the medicine.
Quick tips
- Take Tukavo 50 Tablet under the supervision of a doctor and do not stop taking it unless your doctor advises you to do so.
- Tukavo 50 Tablet may cause diarrhea in some people. Drink plenty of fluids if you are taking this medicine dehydration. If the diarrhea persists, consult your doctor.
- Limited studies suggest that Tukavo 50 Tablet may impair fertility in males and females. If you are planning to have a baby, consult your doctor before taking this medicine.
- Use effective contraception methods during the treatment and at least 1 week after your last dose.
Safety advice

Alcohol

Pregnancy

Breast feeding

Driving

Kidney

Liver
Frequently asked questions
Fact Box
Chemical Class
Habit Forming
Therapeutic Class
Action Class
Related lab tests
References
- Tucatinib [Prescribing Information]. Bothell, WA: Seagen Inc.; 2026. [Accessed 14 Sep. 2026] (online). Available from:
- Central Drugs Standard Control Organization (CDSCO). List of New Drugs approved in the year 2025. [Accessed 14 Sep. 2026] (online). Available from:
- Yang N, Cao J. Safety evaluation of tucatinib: Adverse event signal mining and analysis based on the FAERS database. Medicine (Baltimore). 2025. [Accessed 14 Sep. 2026] (online). Available from:




Want to know more
We provide you with authentic, trustworthy and relevant informationHave issue with the content
Disclaimer
Marketer details
Address: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Ahmedabad-382481
Vendor Details
Lab tests offered by us
- CBC (Complete Blood Count)
- FBS (Fasting Blood Sugar)
- Thyroid Profile Total (T3, T4 & TSH)
- HbA1c (Glycosylated Hemoglobin)
- PPBS (Postprandial Blood Sugar)
- Lipid Profile
- Vitamin D (25-Hydroxy)
- Urine R/M (Urine Routine & Microscopy)
- Coronavirus Covid -19 test- RT PCR
- LFT (Liver Function Test)
- KFT (Kidney Function Test)
- TSH (Thyroid Stimulating Hormone) Ultrasensitive
- ESR (Erythrocyte Sedimentation Rate)
- Uric Acid, Serum
- Vitamin B12
- CRP (C-Reactive Protein), Quantitative
- Urine C/S (Urine Culture and Sensitivity)
- Serum Electrolytes
- Serum Calcium
- Serum Creatinine
- Diabetes Screening (HbA1C & Fasting Sugar)
- KFT with Electrolytes (Kidney Function Test with Electrolytes)
- Cholesterol - Total
- Hb (Hemoglobin)
- Complete Hemogram (CBC & ESR)















